Abilita Therapeutics and Orion Collaborate to Advance Antibodies Development in Oncology and Pain
Shots:
- Abilita and Orion entered into a global license and multi-target research collaboration to advance antibodies for multi-span membrane protein (MMP) targets by leveraging Abilita’s proprietary Enabled Membrane Proteins (EMP) platform
- Under the agreement, Orion will get the exclusive option to license an undisclosed Abilita discovery program upon identifying a development candidate and can nominate two additional MMP targets under the same arrangement while funding all joint discovery efforts
- Moreover, Abilita will receive up to $785M milestone payments for all three targets, plus royalties on commercial sales
Ref: Abilita Therapeutics & Orion | Image: Abilita Therapeutics & Orion
Related News:- Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
